What is Alpha-1 Antitrypsin? Functions, Applications, and Its Importance in Health

Alpha-1 Antitrypsin (AAT) is a critical protein in the human body that helps protect tissues, especially lung and liver, from damage by enzymes from inflammatory cells, especially neutrophil elastase. Did you know that AAT deficiency (AATD) can lead to serious lung and liver conditions? Discover how this protein works and why it's vital for maintaining respiratory and hepatic health.

What is Alpha-1 Antitrypsin?

AAT is a protein primarily synthesized in the liver and released into the bloodstream. It and plays a critical role in protecting lung tissue by inhibiting neutrophil elastase, an enzyme that can degrade connective tissue if left unchecked.

Discovered in the early 1960s, AAT gained greater clinical relevance when researchers linked AATD to early-onset emphysema, chronic obstructive pulmonary disease (COPD), and certain liver conditions. Beyond its protective role in the lungs, AAT regulates inflammation throughout the body, making it a molecule of interest in immunology, pulmonology, and rare disease research.

Importance of Alpha-1 Antitrypsin in Health and the Pharmaceutical Industry

AAT regulates inflammation and protects lung tissue, particularly from the damaging effects of neutrophil elastase. In individuals with AATD -a rare genetic disorder - low AAT levels allow unchecked enzymatic activity, leading to progressive lung damage, early-onset emphysema, and COPD. Additionally, abnormal AAT protein accumulates in liver cells (hepatocytes) which can cause liver fibrosis, cirrhosis, and in some cases, liver cancer (hepatocellular carcinoma).

In the pharmaceutical industry, AAT is the active component in augmentation therapy, a plasma-derived treatment that raises AAT levels in patients with AATD. These therapies are manufactured under strict GMP (Good Manufacturing Practice) conditions to ensure purity, sterility, and efficacy. Innovations in recombinant AAT production and gene therapy platforms are currently being developed to overcome supply limitations and enhance therapeutic accessibility for global patient populations.

Types and Classifications of Alpha-1 Antitrypsin

Alpha-1 Antitrypsin (AAT) is encoded by the SERPINA1 gene, which has multiple genetic variations (alleles). These alleles determine how much AAT is made and how well it works. This determines an individual’s AAT blood levels and the risk of developing associated conditions like chronic obstructive pulmonary disease (COPD) and liver disease.

Normal (MM genotype)

Every person inherits two alleles (one from each parent). Individuals with two M alleles have normal AAT production and function. They are not at increased risk for AAT-related conditions. This is the most common genotype in the general population.

Deficient (ZZ genotype)

The ZZ genotype is the most clinically significant and severe form of AATD. It results in very low serum AAT levels (often <15% of normal), leading to a high risk of early-onset emphysema, particularly in smokers, and liver disease due to accumulation of abnormal AAT protein in hepatocytes.

Intermediate (MZ, SZ genotypes)

Individuals with combinations of two different alleles such as MZ or SZ typically have moderately reduced AAT levels. While many remain asymptomatic, their risk of lung disease increases with environmental exposures, such as smoking, occupational dust, or air pollution. Detrimental effects on the liver are possible but less frequent.

Null variants

These rare mutations (e.g., Q0 alleles) lead to complete absence of AAT production. Individuals with two null alleles (Q0Q0) are at extremely high risk for rapidly progressing lung disease, but typically do not develop liver disease, as the abnormal protein is not retained in the liver.

Understanding AAT genotypes is essential for accurate diagnosis, genetic counselling, risk assessment, and selecting appropriate treatment strategies, including augmentation therapy or participation in gene-based clinical trials.

Process or Functionality of Alpha-1 Antitrypsin

AAT protects tissues from enzymatic damage during inflammation. The following steps outline its biological pathway:

Step 1: Synthesis in the Liver

AAT is primarily synthesized by cells in the liver (hepatocytes). After synthesis, the AAT protein undergoes modifications inside the hepatocyte which are essential for its stability and functionality.

Step 2: Secretion into the Bloodstream

Once modified in the hepatocyte, AAT is secreted into the bloodstream and circulates throughout the body, with high concentrations found in the lungs, where it acts as a defense mechanism during inflammation or infection.

Step 3: Inhibition of Neutrophil Elastase

AAT's primary role is to inhibit neutrophil elastase, a powerful enzyme that breaks down proteins. Neutrophil elastase is released by white blood cells during immune responses. If left unchecked, elastase can degrade elastin and other structural proteins in lung tissue, leading to conditions such as emphysema. AAT binds irreversibly to neutrophil elastase, forming a complex and permanently inactivating the enzyme.

Step 4: Clearance or Recycling

AAT-elastase complexes are then removed from the bloodstream by the liver or immune cells. This process maintains elastase-AAT balance, which is essential to prevent chronic inflammation and tissue damage.

Clinical or Industrial Applications of Alpha-1 Antitrypsin

Alpha-1 Antitrypsin (AAT) plays a growing role in both clinical medicine and pharmaceutical innovation, particularly in the management of inflammatory, pulmonary, and liver-related diseases:

Intravenous Augmentation Therapy

The primary clinical use of AAT is in augmentation therapy for individuals with AATD. Administered intravenously, this therapy supplements the missing or dysfunctional protein, helping to slow the progression of emphysema, reduce lung inflammation, and preserve respiratory function. Studies show improvements in quality of life and reductions in the frequency of exacerbations.

Diagnostic Testing

Diagnostic kits are used in hospitals and labs to measure serum AAT levels and identify genetic variants (e.g., PiZZ, PiSZ and others). Early detection of AATD allows for proactive reduction of risk factors such as smoking, environmental exposure to smoke or dust or behaviours affecting liver health, making diagnostics a critical component of preventive care.

Research in Inflammatory and Autoimmune Diseases

Beyond AATD, researchers are exploring AAT’s effects on inflammation and the immune system in conditions like type 1 diabetes, rheumatoid arthritis, vasculitis, and even organ transplantation. Its ability to regulate protease activity and inflammation make it a potential medication for treating chronic immune disorders.

Gene Therapy and Recombinant Production

Ongoing gene therapy trials aim to correct the underlying genetic defect in AATD, offering a long-term or permanent solution. Additionally, production of AAT - using mammalian or microbial cells - is underway to increase the supply of AAT and ensure greater access around the world.

AAT is a critical protein that protects tissues—especially the lungs—from enzymatic damage caused by inflammation. AATD, though often underdiagnosed, can lead to serious respiratory and hepatic conditions. Fortunately, with advancements in diagnostic tools, AAT augmentation therapies, and emerging biotechnological approaches, patients with AATD have access to increasingly effective treatments.

Want to learn more about related topics? Explore our medical glossary here.